胶质母细胞瘤中IMP3、CD164的表达及临床意义

摘要
图/表
参考文献(26)
相关文章 (1)

全文: PDF (603 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨恶性肿瘤相关基因IMP3、唾液酸黏蛋白CD164在胶质母细胞瘤（GBM）组织中的表达及临床意义。方法收集2011年1月～2015年7月安徽省立医院119例GBM石蜡包埋样本，进行全自动免疫组化检测IMP3、CD164的表达，并与临床病理因素以及患者的生存情况进行统计学分析。结果 IMP3、CD164的高表达率分别为69.7%（83/119）、81.5%（97/119），二者表达水平呈正相关（r = 0.252，P = 0.006）。在与临床资料关系的分析中，IMP3表达与表皮生长因子受体（EGFR）呈正相关（r = 0.242，P = 0.008），与患者性别、年龄、肿瘤大小、肿瘤部位、Ki67增殖指数均无显著相关性（P ＞ 0.05）。CD164表达与患者年龄（r = 0.285，P = 0.002）、EGFR（r = 0.249，P = 0.006）呈正相关，与其他不相关（P ＞ 0.05）。CD164高表达者总生存期（OS）明显短于低表达者（P = 0.004），单独分析IMP3与OS无显著相关性（P = 0.056）。年龄、CD164是GBM的独立预后因素（P = 0.036、0.005）。结论 GBM中CD164的表达与IMP3关系密切，CD164可作为预测GBM预后不良的独立因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴景1
	2 王婧婧2 李晓洁2 何杰2
	3

关键词 ：胶质母细胞瘤, IMP3, CD164, 总生存期

Abstract：Objective To investigate the expression and clinical significance of the oncogene IMP3 and sialomucin CD164 in glioblastoma (GBM) tissues. Methods One hundred and nineteen GBM paraffin-embedded samples from January 2011 to July 2015 in Anhui Provincial Hospital were collected. The expression of IMP3 and CD164 was detected by automated immunohistochemistry. The results were analyzed with clinical and pathological factors and the survival of patients. Results The high expression rates of IMP3 and CD164 were 69.7% (83/119) and 81.5% (97/119) respectively. There was a positive correlation between the two expression levels (r = 0.252, P = 0.006). In the connected analysis with clinical data, the expression of IMP3 was positively correlated with EGFR state (r = 0.242, P = 0.008), and was not significantly related to the gender, age, tumor size, tumor location and Ki67 proliferation index (P ＞ 0.05). CD164 expression was positively correlated with age (r = 0.285，P = 0.002) and EGFR (r = 0.249，P = 0.006), not other factors (P ＞ 0.05). The overall survival (OS) of patients with CD164 high expression were significantly shorter than those with low expression (P = 0.004). There was no significant correlation between IMP3 and OS alone (P = 0.056). Age and CD164 were independent prognostic factors of GBM (P = 0.036, 0.005). Conclusion The expression of CD164 in GBM is closely related to IMP3, and CD164 can be used as an independent predictor of poor prognosis of GBM.

Key words： Glioblastoma IMP3 CD164 Overall survival

基金资助:国家自然科学基金资助项目（81272800）。

通讯作者: 何杰（1962.6-），女，博士，主任医师，教授，博士生导师；研究方向：胶质瘤分子病理。

作者简介: 吴景（1983.12-），女，新乡医学院2015级病理学与病理生理学专业在读硕士研究生；研究方向：肿瘤分子病理学。

引用本文:

吴景1,2 王婧婧2 李晓洁2 何杰2,3. 胶质母细胞瘤中IMP3、CD164的表达及临床意义[J]. 中国医药导报, 2018, 15(13): 4-8.
WU Jing1,2 WANG Jingjing2 LI Xiaojie2 HE Jie2,3. Expression and clinical significance of IMP3 and CD164 in glioblastomas. 中国医药导报, 2018, 15(13): 4-8.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I13/4

[1] Lwin Z，MacFadden D，Al-Zahrani A，et al. Glioblastoma management in the temozolomide era：have we improved outcome? [J]. J Neurooncol，2013，115（2）：303-310.
[2] Findeis-Hosey JJ，Xu H. Insulin-like growth factor Ⅱ-messenger RNA-binding protein-3 and lung cancer [J]. Biotech Histochem，2012，87（1）：24-29.
[3] Lin J，Xu K，Wei J，et al. MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer [J]. Gene Ther，2016，2（1）. Pii：6.
[4] Huang AF，Chen MW，Huang SM，et al. CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1alpha/CXCR4 axis [J]. Mol Cancer，2013，12（1）：115.
[5] Tang J，Zhang L，She X，et al. Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation，mobility，and metastasis in vitro and in vivo [J]. Cancer Invest，2012，30（5）：380-389.
[6] Havens AM，Jung Y，Sun YX，et al. The role of sialomucin CD164（MGC-24v or endolyn）in prostate cancer metastasis [J]. BMC Cancer，2006，6：195.
[7] Neuropathology Group of Pathology Branch of the Chinese Medical A. World Health Organization classification of tumours of the central nervous system：a summary [J]. Zhonghua Bing Li Xue Za Zhi，2016，45（11）：745-747.
[8] Wang Z，Xue Y，Wang P，et al. MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor [J]. Oncol Rep，2016，35（5）：2733-2742.
[9] Codrici E，Enciu AM，Popescu ID，et al. Glioma Stem Cells and Their Microenvironments： Providers of Challenging Therapeutic Targets [J]. Stem Cells Int，2016，2016：5728438.
[10] Watt SM，Buhring HJ，Rappold I，et al. CD164，a novel sialomucin on CD34（+）and erythroid subsets，is located on human chromosome 6q21 [J]. Blood，1998，92（3）：849-866.
[11] Forde S，Tye BJ，Newey SE，et al. Endolyn（CD164）modulates the CXCL12-mediated migration of umbilical cord blood CD133+ cells [J]. Blood，2007，109（5）：1825-1833.
[12] Chen WL，Huang AF，Huang SM，et al. CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling [J]. Oncotarget，2017，8（33）：54115-54135.
[13] Tu M，Cai L，Zheng W，et al. CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma [J]. Mol Med Rep，2017，15（4）：1713-1721.
[14] Brinegar AE，Cooper TA. Roles for RNA-binding proteins in development and disease [J]. Brain Res，2016，1647：1-8.
[15] Samanta S，Sun H，Goel HL，et al. IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG [J]. Oncogene，2016，35（9）：1111-1121.
[16] Palanichamy JK，Tran TM，Howard JM，et al. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation [J]. J Clin Invest，2016，126（4）：1495-1511.
[17] Zhu Q，Qu Y，Zhang Q，et al. IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression [J]. Am J Transl Res，2017，9（7）：3387-3398.
[18] Huang X，Wei Q，Liu J，et al. Analysis of IMP3 expression in primary tumor and stromal cells in patients with colorectal cancer [J]. Oncol Lett，2017，14（6）：7304-7310.
[19] Riener MO，Hoegel J，Iro H，et al. IMP3 and p16 expression in squamous cell carcinoma of the head and neck：A comparative immunohistochemical analysis [J]. Oncol Lett，2017，14（2）：1665-1670.
[20] Zhao W，Lu D，Liu L，et al. Insulin-like growth factor 2 mRNA binding protein 3（IGF2BP3）promotes lung tumorigenesis via attenuating p53 stability [J]. Oncotarget，2017，8（55）：93672-93687.
[21] Zhang J，Ji Q，Jiao C，et al. IGF2BP3 as a potential tissue marker for the diagnosis of esophageal high-grade intraepithelial neoplasia [J]. Onco Targets Ther，2017，10：3861-3866.
[22] Zhou Y，Huang T，Siu HL，et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis [J]. Mol Cancer，2017，16（1）：77.
[23] Burdelski C，Jakani-Karimi N，Jacobsen F，et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features： A tissue microarray study on 8，877 human cancers and normal tissues [J]. Oncol Rep，2018，39（1）：3-12.
[24] Chen L，Xie Y，Li X，et al. Prognostic value of high IMP3 expression in solid tumors：a meta-analysis [J]. Onco Targets Ther，2017，10：2849-2863.
[25] Bhargava S，Visvanathan A，Patil V，et al. IGF2 mRNA binding protein 3（IMP3）promotes glioma cell migration by enhancing the translation of RELA/p65 [J]. Oncotarget，2017，8（25）：40469-40485.
[26] Taniuchi K，Furihata M，Hanazaki K，et al. IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer [J]. Oncotarget，2014，5（16）：6832-6845.